{"Title": "Do increased tumor infiltrating lymphocytes co-existing with Homologous Recombination Deficiency provide clues to enhance immunotherapy of ovarian cancer?", "Year": 2019, "Source": "Gynecol. Oncol.", "Volume": "153", "Issue": 2, "Art.No": null, "PageStart": 213, "PageEnd": 214, "CitedBy": 0, "DOI": "10.1016/j.ygyno.2019.04.014", "Link": "https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85064477531&origin=inward", "Abstract": null, "AuthorKeywords": null, "IndexKeywords": ["Antineoplastic Agents, Immunological", "Antineoplastic Combined Chemotherapy Protocols", "BRCA1 Protein", "BRCA2 Protein", "Clinical Trials as Topic", "Female", "Humans", "Immunotherapy", "Lymphocytes, Tumor-Infiltrating", "Mutation", "Ovarian Neoplasms", "Poly(ADP-ribose) Polymerase Inhibitors", "Programmed Cell Death 1 Receptor", "Recombinational DNA Repair", "Treatment Outcome"], "DocumentType": "Journal", "PublicationStage": null, "OpenAccess": 2, "EID": "2-s2.0-85064477531", "SubjectAreas": [["Oncology", "MEDI", "2730"], ["Obstetrics and Gynecology", "MEDI", "2729"]], "AuthorData": {"7007134127": {"Name": "Ledermann J.", "AuthorID": "7007134127", "AffiliationID": "60109234, 60022148", "AffiliationName": "UCL Cancer Trials Centre, UCL Cancer Institute"}}}